De Facto Communications is pleased to announce that they have been appointed by Xention Ltd as its full-service communications agency. Founded in 2002, Xention is a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs.
Xention Ltd is a leader in the discovery and development of ion channel-modulating drugs. The Company’s potential breakthrough drugs in clinical development include XEN-D0101, a new atrial selective potassium channel blocker for atrial fibrillation, and XEN-D0501, a novel ion channel modulator for the treatment of overactive bladder. Xention also has preclinical research programmes in atrial fibrillation, pain and autoimmune disease. The Company uses proprietary ion channel expertise and technologies to accelerate the discovery of potent and selective ion channel drugs. In particular, Xention is a leader in the use of true electrophysiological data, ion channel chemoinformatics and experienced medicinal chemistry to identify potent new small molecule drugs in this rapidly evolving field of medicine.
Commenting on the win, Mike Wort, Managing Director of De Facto said: “Xention is one of the most vibrant companies to emerge in a long time. The company’s technology in ion-channel biology and chemistry is allowing it to developnew ways of regulating ion channels in disease and creating potential breakthroughs in clinical medicine. We are delighted to be involved in helping the Company pursue its vision of leadership in the biopharmaceutical sector”.
-END-
For further information, please contact:
Anna Dunphy Tel: +44 207 861 3838
De Facto Communications
Notes to Editor:
About De Facto Communication
De Facto Communications is part of the Bell Pottinger Group and is one of Europe's most successful public relations consultancies in life science, healthcare, medical education and clinical trials marketing. In partnership with their clients, they approach their work with a passion and commitment that delivers award-winning, integrated communications programmes based on effective strategy, original thinking and creativity. De Facto is headquartered in London and operates internationally with clients across Europe and the US. Further information on De Facto Communications can be found at www.defacto.com
